TCS Ranked as the #1 Life Sciences Service Provider by HFS

Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been ranked #1 in the HFS Top 10 Life Sciences Service Providers Report[1].

The report highlights TCS’ strong domain expertise across the life sciences value chain, as a key strength. It goes on to say that TCS’ IP-led go-to-market approach that allows it to capture emerging opportunities in genomics, bio-informatics, connected devices, and 3-D printing by leveraging the TCS COIN ecosystem, was cited as a strength. The report also highlights TCS’ Digital platforms for life sciences, including the award-winning TCS Advanced Drug Development (ADD) platform suite, the Decision FabricTM engine, TCS Connected Clinical TrialsTM and Cognitive Commercial Intelligence (CCI) Platform.

Life sciences and healthcare companies are leveraging emerging technologies such as AI, IoT and blockchain to create a hyper-connected ecosystem and forging a path for patient-centric care,” said Debashis Ghosh, Business Group Head, Life Sciences and Healthcare, TCS. “This #1 ranking by an independent third-party research firm is a strong validation of our ability to execute on a clear transformation vision for the life sciences industry, growth backed by innovation and continuous investments in platform solutions, and ability to consistently create business value for customers.”

TCS works with leading life sciences companies to accelerate their business transformation journey by leveraging its Business 4.0TM framework and Machine First™ Delivery Model (MFDMTM). TCS offers a full set of IT and business process capabilities including regulatory services, predictive and prescriptive analytics, genomics research, advanced platform solutions for the entire clinical R&D value chain, medical device engineering, supply chain and manufacturing and sales and marketing. Early investments in re-skilling the workforce, building agile workplaces, and developing an extensive portfolio of intellectual property have helped TCS gain significant scale and depth across life sciences value chain.

TCS ADD is a suite of cloud-based platforms that leverage next-gen digital technologies such as automation, AI, and IoT to transform the entire clinical R&D value chain. TCS’ CCI platform provides transformational and flexible analytics solutions to help the sales, marketing, pricing and market access functions within life sciences organizations make smarter decisions at scale. The TCS Real World Evidence platform provides end-to-end value evidence lifecycle management capabilities including real world data, knowledge and evidence management, study conduct and management, evidence generation and synthesis and value communication.

TCS’ experts in the life sciences domain work closely with solution architects to come up with innovative solutions that use a combination of user-friendly digital platforms, clinical services KPO, AI, IoT/wearables, big data, 3-D printing, RPA, blockchain and cloud to achieve better speed to market and superior business outcomes.

“The role of third-party service providers in the life sciences industry is no longer just supporting ‘business-as-usual’, but to help enterprises drive ‘meaningful change’. With investments in platforms such as the TCS – ADD Suite of platforms, TCS Connected Clinical Trials platform, and Cognitive Commercial Intelligence Platform, TCS brings to the table an IP-focused and platform-based offering set backed by strong domain expertise to do just that,” said Saurabh Gupta, Chief Research Officer, HFS Research.

Our ability to drive large scale digital transformation, continuous investments in intellectual property, and depth of digital talent and capabilities, position us as a preferred transformation partner for our customers in the life sciences industry,” added Debashis Ghosh.

Comments are closed, but trackbacks and pingbacks are open.